

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 63339

**Title:** Metal-organic framework IRMOFs coated with a temperature-sensitive gel (IRMOF-3-Gel) delivering norcantharidin (NCTD) to treat liver cancer

**Reviewer's code:** 05491991

**Position:** Peer Reviewer

**Academic degree:** FRCPE, MD, PhD

**Professional title:** Professor, Research Associate

**Reviewer's Country/Territory:** Italy

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-25

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-02 03:48

**Reviewer performed review:** 2021-03-29 10:08

**Review time:** 27 Days and 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

#### **SPECIFIC COMMENTS TO AUTHORS**

This is an interesting study about the NCTD in the treatment of liver cancer. In this study a foundation for the liver-targeting ability of NCTD-IRMOF-3-Gel was developed. The methods are reasonable, and the interesting is very interesting. In my opinion, after a minor editing, this manuscript can be accepted.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 63339

**Title:** Metal-organic framework IRMOFs coated with a temperature-sensitive gel (IRMOF-3-Gel) delivering norcantharidin (NCTD) to treat liver cancer

**Reviewer's code:** 05491990

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Australia

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-25

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-02 03:48

**Reviewer performed review:** 2021-04-12 10:14

**Review time:** 41 Days and 6 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

Norcantharidin is suitable for the treatment of primary liver cancer, especially early and middle primary liver cancer. Compared to that of cantharidin, the toxicity of Norcantharidin is reduced to a large extent, but it still has a certain degree of urinary system toxicity, and organ toxicity occurs with large doses or long-term use, so there is a strict limit on the maximum dosage of Norcantharidin in the clinic. Most of the Norcantharidin injections used in the clinic are the sodium salt, and its pH value is approximately 9.0, which makes it more irritating. When Norcantharidin-IRMOF-3 enters the body, burst release will be caused due to endocytosis or gastrointestinal absorption. In this study, the authors developed a nanomaterial carrier, NCTD-loaded metal-organic framework IRMOF-3 coated with a temperature-sensitive gel, and aimed to improve the anticancer activity and reduce the drug dose. This study is very well designed, the results are interesting. Comments 1. The manuscript is very well written. However, the manuscript requires an editing. Some minor language polishing should be corrected. And the format should be updated according to the guideline of the journal. 2. Figures are good. But please move the figures to the end of the manuscript. And the quality of the images should be updated. If the figure 2 and figure 3 can change to color images, it will be better. 3. Please double check the Equations in table 1. 4 Please edit the references list.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 63339

**Title:** Metal-organic framework IRMOFs coated with a temperature-sensitive gel (IRMOF-3-Gel) delivering norcantharidin (NCTD) to treat liver cancer

**Reviewer's code:** 03664730

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Research Associate

**Reviewer's Country/Territory:** United Kingdom

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-25

**Reviewer chosen by:** Jin-Lei Wang

**Reviewer accepted review:** 2021-03-29 10:03

**Reviewer performed review:** 2021-04-12 10:15

**Review time:** 14 Days

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This is an interesting study of norcantharidin in the treatment of liver cancer. The manuscript requires a minor editing before final publication.